SRR11296852
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.630
- MTORC1_SIGNALING+0.500
- E2F_TARGETS+0.440
- MYC_TARGETS_V2+0.440
- G2M_CHECKPOINT+0.410
- OXIDATIVE_PHOSPHORYLATION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.350
- ALLOGRAFT_REJECTION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- PI3K_AKT_MTOR_SIGNALING+0.300
Top 10 suppressed
- MYOGENESIS-0.310
- APICAL_SURFACE-0.260
- KRAS_SIGNALING_DN-0.240
- UV_RESPONSE_DN-0.210
- APICAL_JUNCTION-0.170
- TGF_BETA_SIGNALING-0.170
- COAGULATION-0.150
- NOTCH_SIGNALING-0.140
- ESTROGEN_RESPONSE_EARLY-0.120
- INTERFERON_ALPHA_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-46-3765-01A-01R-0980-07 | — | cohortSQ2 | 0.865 |
| 2 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.848 |
| 3 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.846 |
| 4 | TCGA-C4-A0F0-01A-12R-A10U-07 | — | — | 0.843 |
| 5 | SRR35579824 | — | E | 0.839 |
| 6 | SRR12696741 | — | — | 0.839 |
| 7 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.838 |
| 8 | BS_5CTVXVRX | high-grade glioma | — | 0.837 |
| 9 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.836 |
| 10 | TCGA-18-4721-01A-01R-1443-07 | — | cohortSQ2 | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.630 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |